A new meta-analysis commissioned by WHO informs updated treatment guidelines for uncomplicated malaria in the first trimester of pregnancy. The study finds that artemether-lumefantrine is as safe and possibly more effective than non-artemisinin-based treatments, including quinine, with significant reductions in adverse pregnancy outcomes.
A new study using pooled individual patient data from over 70,000 patients has found that artemisinin-based combination therapy can suppress the bone marrow response and contribute to anaemia. The analysis identified patients at greatest risk of severe anaemia and highlights potential advantages of alternative treatment regimens.
Limited evidence on VL treatment during pregnancy highlights liposomal amphotericin B as a safer choice. Existing therapeutic guidelines are based on limited data and often rely on personal experience.
A systematic review and meta-analysis found that Ivermectin is as safe and well-tolerated in children under 15kg as it is in heavier individuals. The study suggests that millions of young children are denied access to treatment due to outdated safety data, highlighting the need for equitable access to Ivermectin.
A study found that artemisinin-based combination therapies (ACTs) were significantly more effective than quinine in treating malaria in pregnant women. ACTs, such as artemether-lumefantrine, showed better tolerability and efficacy compared to quinine, with lower recurrence rates of malaria after treatment.
Researchers found that severely malnourished children have lower exposure to the antimalarial drug lumefantrine, resulting in increased risk of therapeutic failure and new malaria infections. Malnutrition affects absorption, distribution, metabolism, or elimination of drugs in these children.
A new study of malaria medicine quality in sub-Saharan African countries found that up to 42% of the private-sector market is made up of non-quality-assured (QA) treatments, which can impact patient health and safety. The study's findings highlight the need for policy responses to address the growing market for QA medicines.
A lineage of multidrug-resistant P. falciparum malaria parasites has spread across Cambodia, Laos, and Thailand, causing high treatment failure rates for main malaria medicines. The emergence of these superbugs poses a significant threat to global malaria control and eradication efforts.
Fake medicines have been a problem since the first manufacture, with thousands of 'Third Men' hiding in today's world. Investment in medicine regulatory authorities is crucial to combat substandard and falsified medicines that can drive antimicrobial resistance.